Survival Curve from Scientific Research

Shown via Kaplan–Meier curves, median progression-free survival (PFS) was longer for those whose corresponding baseline ctDNA harbored clonal multiple PIK3CA mut vs subclonal multiple PIK3CA mut and were treated with either placebo + fulvestrant [median PFS (mPFS) = 3.9 vs 2.0 months, respectively; Hazard Ratio (HR) = 0.19 (95% CI, 0.051–0.73), p = 0.025] or with taselisib + fulvestrant [mPFS = 7.6 vs 5.1 months, respectively; HR = 0.37 (95% CI, 0.16–0.87), p = 0.027]. See Methods on details for calculations and statistics of ORR and PFS. mut, mutation(s); n, number of study participants or samples in the indicated subgroup

DOI